blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP1945217

EP1945217 - COMBINATIONS COMPRISING A VEGF RECEPTOR INHIBITOR AND A PENETRATION ENHANCER [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  08.03.2013
Database last updated on 05.10.2024
Most recent event   Tooltip18.07.2014Lapse of the patent in a contracting state
New state(s): HU		published on 20.08.2014  [2014/34]
Applicant(s)For all designated states
Novartis AG
Lichtstrasse 35
4056 Basel / CH
[2012/18]
Former [2008/30]For all designated states
Novartis AG
Lichtstrasse 35
4056 Basel / CH
Inventor(s)01 / BILLICH, Andreas
Novartis Institutes for Biomedical
Research GmbH & Co KG
Brunner Strasse 59
A-1235 Vienna / AT
02 / STÜTZ, Anton
Novartis Institutes for Biomedical
Research GmbH & Co KG
Brunner Strasse 59
A-1235 Wien / AT
 [2012/18]
Former [2008/30]01 / BILLICH, Andreas
Novartis Institutes for Biomedical Research GmbH & Co KG Brunner Strasse 59
A-1235 Vienna / AT
02 / STÜTZ, Anton
Novartis Institutes for Biomedical Research GmbH & Co KG Brunner Strasse 59
A-1235 Wien / AT
Representative(s)Lettenbichler-Ager, Isolde Maria
Novartis Pharma AG
Patent Department
4002 Basel / CH
[N/P]
Former [2012/18]Lettenbichler-Ager, Isolde Maria
Novartis Pharma AG Patent Department
4002 Basel / CH
Former [2008/30]Lettenbichler, Isolde Maria
Novartis Pharma AG Patent Department
4002 Basel / CH
Application number, filing date06791989.412.09.2006
[2008/30]
WO2006EP08857
Priority number, dateGB2005001867113.09.2005         Original published format: GB 0518671
GB2005001867213.09.2005         Original published format: GB 0518672
[2008/30]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2007031265
Date:22.03.2007
Language:EN
[2007/12]
Type: A2 Application without search report 
No.:EP1945217
Date:23.07.2008
Language:EN
The application published by WIPO in one of the EPO official languages on 22.03.2007 takes the place of the publication of the European patent application.
[2008/30]
Type: B1 Patent specification 
No.:EP1945217
Date:02.05.2012
Language:EN
[2012/18]
Search report(s)International search report - published on:EP12.07.2007
ClassificationIPC:A61K31/505, A61K31/506, A61K31/519, A61K31/538, A61K31/501, A61K31/44, A61K9/00, A61K9/70, A61K9/48, A61K47/10, A61K47/20, A61P17/00, A61P17/06, A61P17/10
[2011/46]
CPC:
A61K9/0014 (EP,US); A61K31/505 (EP,KR,US); A61K31/44 (EP,US);
A61K31/501 (EP,US); A61K31/506 (EP,KR,US); A61K31/519 (EP,KR,US);
A61K31/538 (EP,KR,US); A61K47/10 (EP,US); A61K47/20 (EP,US);
A61K9/4858 (EP,US); A61P17/00 (EP); A61P17/02 (EP);
A61P17/06 (EP); A61P17/10 (EP); A61P37/08 (EP);
A61P43/00 (EP) (-)
Former IPC [2008/30]A61K31/505, A61K31/506, A61K31/519, A61K31/538, A61K31/501, A61K31/44, A61K9/70, A61P17/00, A61P17/06, A61P17/10
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2008/30]
TitleGerman:KOMBINATIONEN AUS EINEM VEGF-REZEPTOR-HEMMER UND EINEM PENETRATIONSVERSTÄRKER[2008/30]
English:COMBINATIONS COMPRISING A VEGF RECEPTOR INHIBITOR AND A PENETRATION ENHANCER[2008/30]
French:COMBINAISONS COMPRENANT UN INHIBITEUR DES RÉCEPTEURS VEGF ET UN AGENT AMÉLIORANT LA PÉNÉTRATION[2011/46]
Former [2008/30]COMBINAISONS COMPRENANT UN INHIBITEUR DES RECEPTEURS VEGF
Entry into regional phase14.04.2008National basic fee paid 
14.04.2008Designation fee(s) paid 
14.04.2008Examination fee paid 
Examination procedure14.04.2008Examination requested  [2008/30]
16.02.2009Despatch of a communication from the examining division (Time limit: M06)
13.10.2009Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time
09.12.2009Reply to a communication from the examining division
05.11.2010Despatch of a communication from the examining division (Time limit: M04)
23.02.2011Reply to a communication from the examining division
02.11.2011Communication of intention to grant the patent
12.03.2012Fee for grant paid
12.03.2012Fee for publishing/printing paid
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  16.02.2009
Opposition(s)05.02.2013No opposition filed within time limit [2013/15]
Request for further processing for:The application is deemed to be withdrawn due to failure to reply to the examination report
09.12.2009Request for further processing filed
09.12.2009Full payment received (date of receipt of payment)
Fees paidRenewal fee
15.09.2008Renewal fee patent year 03
11.09.2009Renewal fee patent year 04
14.09.2010Renewal fee patent year 05
30.09.2011Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU12.09.2006
AT02.05.2012
BE02.05.2012
CY02.05.2012
CZ02.05.2012
DK02.05.2012
EE02.05.2012
FI02.05.2012
IT02.05.2012
LT02.05.2012
LV02.05.2012
NL02.05.2012
PL02.05.2012
RO02.05.2012
SE02.05.2012
SI02.05.2012
SK02.05.2012
TR02.05.2012
BG02.08.2012
GR03.08.2012
ES13.08.2012
IS02.09.2012
PT03.09.2012
GB12.09.2012
IE12.09.2012
LU12.09.2012
CH30.09.2012
LI30.09.2012
MC30.09.2012
FR01.10.2012
[2014/34]
Former [2014/27]AT02.05.2012
BE02.05.2012
CY02.05.2012
CZ02.05.2012
DK02.05.2012
EE02.05.2012
FI02.05.2012
IT02.05.2012
LT02.05.2012
LV02.05.2012
NL02.05.2012
PL02.05.2012
RO02.05.2012
SE02.05.2012
SI02.05.2012
SK02.05.2012
TR02.05.2012
BG02.08.2012
GR03.08.2012
ES13.08.2012
IS02.09.2012
PT03.09.2012
GB12.09.2012
IE12.09.2012
LU12.09.2012
CH30.09.2012
LI30.09.2012
MC30.09.2012
FR01.10.2012
Former [2014/21]AT02.05.2012
BE02.05.2012
CY02.05.2012
CZ02.05.2012
DK02.05.2012
EE02.05.2012
FI02.05.2012
IT02.05.2012
LT02.05.2012
LV02.05.2012
NL02.05.2012
PL02.05.2012
RO02.05.2012
SE02.05.2012
SI02.05.2012
SK02.05.2012
TR02.05.2012
BG02.08.2012
GR03.08.2012
ES13.08.2012
IS02.09.2012
PT03.09.2012
GB12.09.2012
IE12.09.2012
CH30.09.2012
LI30.09.2012
MC30.09.2012
FR01.10.2012
Former [2013/46]AT02.05.2012
BE02.05.2012
CY02.05.2012
CZ02.05.2012
DK02.05.2012
EE02.05.2012
FI02.05.2012
IT02.05.2012
LT02.05.2012
LV02.05.2012
NL02.05.2012
PL02.05.2012
RO02.05.2012
SE02.05.2012
SI02.05.2012
SK02.05.2012
BG02.08.2012
GR03.08.2012
ES13.08.2012
IS02.09.2012
PT03.09.2012
GB12.09.2012
IE12.09.2012
CH30.09.2012
LI30.09.2012
MC30.09.2012
FR01.10.2012
Former [2013/40]AT02.05.2012
BE02.05.2012
CY02.05.2012
CZ02.05.2012
DK02.05.2012
EE02.05.2012
FI02.05.2012
IT02.05.2012
LT02.05.2012
LV02.05.2012
NL02.05.2012
PL02.05.2012
RO02.05.2012
SE02.05.2012
SI02.05.2012
SK02.05.2012
BG02.08.2012
GR03.08.2012
IS02.09.2012
PT03.09.2012
GB12.09.2012
IE12.09.2012
CH30.09.2012
LI30.09.2012
MC30.09.2012
FR01.10.2012
Former [2013/34]AT02.05.2012
BE02.05.2012
CY02.05.2012
CZ02.05.2012
DK02.05.2012
EE02.05.2012
FI02.05.2012
IT02.05.2012
LT02.05.2012
LV02.05.2012
NL02.05.2012
PL02.05.2012
RO02.05.2012
SE02.05.2012
SI02.05.2012
SK02.05.2012
BG02.08.2012
GR03.08.2012
IS02.09.2012
PT03.09.2012
GB12.09.2012
IE12.09.2012
CH30.09.2012
LI30.09.2012
MC30.09.2012
Former [2013/33]AT02.05.2012
BE02.05.2012
CY02.05.2012
CZ02.05.2012
DK02.05.2012
EE02.05.2012
FI02.05.2012
IT02.05.2012
LT02.05.2012
LV02.05.2012
NL02.05.2012
PL02.05.2012
RO02.05.2012
SE02.05.2012
SI02.05.2012
SK02.05.2012
GR03.08.2012
IS02.09.2012
PT03.09.2012
IE12.09.2012
CH30.09.2012
LI30.09.2012
MC30.09.2012
Former [2013/20]AT02.05.2012
BE02.05.2012
CY02.05.2012
CZ02.05.2012
DK02.05.2012
EE02.05.2012
FI02.05.2012
IT02.05.2012
LT02.05.2012
LV02.05.2012
NL02.05.2012
PL02.05.2012
RO02.05.2012
SE02.05.2012
SI02.05.2012
SK02.05.2012
GR03.08.2012
IS02.09.2012
PT03.09.2012
MC30.09.2012
Former [2013/11]AT02.05.2012
BE02.05.2012
CY02.05.2012
CZ02.05.2012
DK02.05.2012
EE02.05.2012
FI02.05.2012
IT02.05.2012
LT02.05.2012
LV02.05.2012
NL02.05.2012
PL02.05.2012
RO02.05.2012
SE02.05.2012
SI02.05.2012
SK02.05.2012
GR03.08.2012
IS02.09.2012
PT03.09.2012
Former [2013/10]AT02.05.2012
BE02.05.2012
CY02.05.2012
CZ02.05.2012
DK02.05.2012
EE02.05.2012
FI02.05.2012
LT02.05.2012
LV02.05.2012
NL02.05.2012
PL02.05.2012
RO02.05.2012
SE02.05.2012
SI02.05.2012
SK02.05.2012
GR03.08.2012
IS02.09.2012
PT03.09.2012
Former [2013/09]AT02.05.2012
BE02.05.2012
CY02.05.2012
DK02.05.2012
EE02.05.2012
FI02.05.2012
LT02.05.2012
LV02.05.2012
NL02.05.2012
PL02.05.2012
SE02.05.2012
SI02.05.2012
GR03.08.2012
IS02.09.2012
PT03.09.2012
Former [2013/08]AT02.05.2012
BE02.05.2012
CY02.05.2012
DK02.05.2012
FI02.05.2012
LT02.05.2012
LV02.05.2012
NL02.05.2012
PL02.05.2012
SE02.05.2012
SI02.05.2012
GR03.08.2012
IS02.09.2012
PT03.09.2012
Former [2013/07]AT02.05.2012
BE02.05.2012
CY02.05.2012
FI02.05.2012
LT02.05.2012
LV02.05.2012
PL02.05.2012
SE02.05.2012
SI02.05.2012
GR03.08.2012
IS02.09.2012
PT03.09.2012
Former [2013/04]BE02.05.2012
CY02.05.2012
FI02.05.2012
LT02.05.2012
LV02.05.2012
PL02.05.2012
SE02.05.2012
SI02.05.2012
GR03.08.2012
IS02.09.2012
PT03.09.2012
Former [2013/01]CY02.05.2012
FI02.05.2012
LT02.05.2012
LV02.05.2012
PL02.05.2012
SE02.05.2012
SI02.05.2012
GR03.08.2012
IS02.09.2012
PT03.09.2012
Former [2012/51]CY02.05.2012
FI02.05.2012
LT02.05.2012
LV02.05.2012
PL02.05.2012
SE02.05.2012
SI02.05.2012
GR03.08.2012
IS02.09.2012
Former [2012/50]CY02.05.2012
FI02.05.2012
LT02.05.2012
LV02.05.2012
PL02.05.2012
SE02.05.2012
GR03.08.2012
IS02.09.2012
Former [2012/49]CY02.05.2012
FI02.05.2012
LT02.05.2012
PL02.05.2012
SE02.05.2012
IS02.09.2012
Former [2012/48]FI02.05.2012
LT02.05.2012
SE02.05.2012
Former [2012/47]LT02.05.2012
Cited inInternational search[A]US6355657  (OSBORNE DAVID W [US]) [A] 9 * column 1, lines 10-14 * * column 2, lines 8-30 * * column 3, lines 12-21 * * claims 6,7 *;
 [A]EP1415987  (EISAI CO LTD [JP]) [A] 1,2,4,12-18 * page 56, paragraphs 204-207 * * pages 60-62; examples pharmacological-test-example-3 * * page 66, paragraph 244 * * page 310, lines 40-45 * * page 311, lines 20-25,50-55 *;
 [X]WO2005021553  (PFIZER [US], et al) [X] 1-4,10-18 * page 1, lines 4-7 * * page 12, lines 6-31 * * page 18, lines 8-26,35-37 * * page 35, lines 28,29 * * examples 16-28 * * page 89, lines 4-11 *;
 [A]EP1522540  (EISAI CO LTD [JP]) [A] 1,2,4,12-18 * page 40, paragraphs 147,148 * * pages 42-44; examples pharmacological-test-example-2 * * page 130, lines 45-50; examples 90-2 * * page 132, lines 5-10; examples 134-1 * * page 133, lines 5-10; examples 176-1 * * page 142, paragraphs 612-614 * * claims 1,43 *;
 [X]WO2005070891  (AMGEN INC [US]) [X] 1-6,10-18 * page 46, lines 10-14 * * page 47, lines 19-23 * * page 49, lines 3,4 * * page 57, lines 24-29 * * compounds 149-155,179-196,241,363-378,380-396,398-403 * * compounds 421-456,458-460,464,471,503-515,517-537,666-685 * * compounds 783-795 * * page 406, lines 15-30 *;
 [X]WO2005069906  (UNIV YALE [US], et al) [X] 1,10-18 * page 10, lines 23-31 * * page 16, lines 23-29 * * page 17, line 27 - page 18, line 1 * * page 26, lines 11-18 * * page 28, lines 14,15 * * page 34, lines 3-10 * * claims 1,2 *;
 [A]EP1568368  (SCHERING AG [DE]) [A] 1,10-18 * page 3, paragraph 1 * * page 14, paragraph 35 * * page 16, paragraphs 54,57 * * page 17, paragraphs 64,67 * * page 18, paragraph 78 *;
 [PA]WO2006059234  (NOVARTIS AG [CH], et al) [PA] 1-6,9-18 * page 1, paragraph 1 * * page 1, paragraph 4 - page 2, paragraph L * * page 13, paragraph L - page 14, paragraph 2 * * page 15, paragraph 2 - page 16, paragraph 1 * * page 23, paragraph 3 * * page 24, paragraph 3 * * example - ** claim - *;
 [A]  - T.C.K. CHAN, "Percutaneous penetration enhancers: an update", PROCEEDINGS OF THE 9TH BIENNAL INTERNATIONAL CONFERENCE OF PERSPECTIVES IN PERCUTANEOUS PENETRATION, (200501), pages 18 - 22, XP002416625 [A] * page 18, column 1, paragraph 1 - page 19, column 2, paragraph 2 * * page 20, column 1, paragraphs 2-4 * * page 22, column 2, paragraph 3 *
by applicantWO03099771
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.